NACCME released survey results assessing medical education needs in biosimilars

May 31, 2013 10:41 AM

North American for Continuing Medical Education, LLC (NACCME) announced the results of a survey of oncologists, rheumatologists, managed care professionals, pharmacists, and primary care learners.

The study, conducted in April 2013, focused on awareness of and need for information on biosimilar agents, with results strongly supporting the need for comprehensive education on this topic.

Over 400 health professionals participated in the survey, revealing:

  • More than half of respondents said their understanding of the differences between biosimilars versus generics was only fair to poor
  • Over 67% of survey participants indicated an understanding of the difference between biosimilars and reference biologics as fair or poor
  • 77% of respondents rated their understanding of regulatory approval pathway for biosimilars as fair or poor

“It is crucial to get an accurate view of how health professionals view biosimilars in order to assess and address the confusion surrounding this emerging and critical area of need,” said Randy Robbin, President of NACCME. “This survey helps demonstrate the need to provide activities that improve knowledge and address areas of practice like safety monitoring and therapy selection for biosimilars.”

Among other important findings, an overwhelming 97% of survey respondents felt that continuing education on biosimilars was at least somewhat important and three-quarters of those surveyed indicated biosimilars continuing education was important or very important to their practice. Click here to download the full survey report.


Source: NACCME

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!